Summary of Vanda Pharmaceuticals Q3 2025 Earnings Call

1Key Financial Results and Metrics

Total Revenues: $56.3 million for Q3 2025, an 18% increase year-over-year and a 7% increase from Q2 2025.

Net Product Sales:

Fanapt: $31.2 million, up 31% year-over-year and 7% quarter-over-quarter.

HETLIOZ: $18 million, a slight increase of 1% year-over-year and 11% from Q2 2025.

PONVORY: $7 million, a 20% increase year-over-year but a 1% decrease from Q2 2025.

Net Loss: $22.6 million for Q3 2025, compared to a loss of $5.3 million in Q3 2024.

Operating Expenses: $87.5 million, a significant increase from $58.7 million in Q3 2024, driven by higher SG&A and R&D expenses.

Cash Position: $293.8 million as of September 30, 2025, down from $374.7 million at the end of 2024.

2Strategic Updates and Business Highlights

Strong commercial execution with a 31% increase in Fanapt sales attributed to its new bipolar I indication.

Expansion of the Fanapt sales force to approximately 300 representatives, enhancing market reach.

HETLIOZ maintains market share despite generic competition, with ongoing efforts to manage inventory levels at specialty pharmacies.

Vanda is investing in commercial infrastructure and brand visibility through targeted sponsorships and a direct-to-consumer campaign.

Regulatory progress includes ongoing reviews for tradipitant (motion sickness) and Bysanti (bipolar I disorder and schizophrenia), with key PDUFA dates set for December 30, 2025, and February 21, 2026, respectively.

3Forward Guidance and Outlook

Revised revenue guidance for 2025 is now projected between $210 million and $230 million, down from a previous range of $210 million to $250 million.

Year-end cash guidance adjusted to between $260 million and $290 million, reflecting significant investments in commercial infrastructure and R&D.

Continued growth in Fanapt sales is expected, with potential acceleration from the expanded sales force.

4Bad News, Challenges, or Points of Concern

Net Loss Increase: The net loss for the first nine months of 2025 is significantly higher than the previous year, raising concerns about financial sustainability.

HETLIOZ Sales Volatility: Future sales may be impacted by inventory management at specialty pharmacies and ongoing generic competition, leading to potential revenue variability.

Cash Decrease: A notable decline in cash reserves raises concerns about liquidity and the ability to fund ongoing operations and investments.

Regulatory Risks: The outcomes of pending FDA reviews for tradipitant and Bysanti remain uncertain, with potential implications for future revenue.

5Notable Q&A Insights

FDA Interactions: Management expressed optimism regarding the collaborative framework established with the FDA, particularly for tradipitant, with a decision expected by December 30, 2025.

PONVORY Growth: Future quarterly growth for PONVORY is anticipated as the sales force becomes fully operational, with underlying patient demand showing positive trends.

Commercial Strategy for New Products: Vanda plans consumer-centric marketing strategies for tradipitant and HETLIOZ, leveraging direct-to-consumer campaigns to enhance brand awareness.

Bysanti Launch Strategy: Discussions around potential commercial incentives to encourage switching from Fanapt to Bysanti, emphasizing the importance of promotional strategies in a competitive market. This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, and challenges faced by Vanda Pharmaceuticals, providing a comprehensive overview of their Q3 2025 earnings call.